Massachusetts General Hospital is launching a prospective trial of an artificial intelligence tool designed to predict patients’ risk of lung cancer, a crucial area of inquiry amid a rising incidence of the disease in never-smokers.
The trial, to begin later this year, will test the accuracy and usefulness of an AI system the hospital developed with researchers at the Massachusetts Institute of Technology’s Jameel Clinic. The tool stands out from a crowd of similar models in that it predicts a patient’s cancer risk over six years by analyzing a single low-dose CT scan — without the use of other demographic or medical information, or a radiologist’s annotation.
The goal is to help identify which patients would benefit from additional testing and closer management, filling a crucial gap in screening that allows too many tumors to grow undetected.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
